YI
111, Inc.Company with tickers: YI
CIK
1738906
CUSIP
68247Q201
Shares Outstanding
5,196,964
Website
https://corporate.111.com.cn
13F Activity (30d)
1 filings
1 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | 12,556,023,000 | CNY | 2025-12-31 | 20-F | 2026-04-30 |
| Cost of Revenue | — | ||||
| Gross Profit | 723,406,000 | CNY | 2025-12-31 | 20-F | 2026-04-30 |
| Operating Expenses | — | ||||
| Research & Development | — | ||||
| Operating Income | -2,377,000 | CNY | 2025-12-31 | 20-F | 2026-04-30 |
| Net Income | — | ||||
| EPS (Basic) | -0.38 | CNY/shares | 2025-12-31 | 20-F | 2026-04-30 |
| EPS (Diluted) | -0.38 | CNY/shares | 2025-12-31 | 20-F | 2026-04-30 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (CNY)
| Component | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Product | 13,403,436,000 | 14,841,910,000 | 14,294,740,000 | 12,470,647,000 |
| Business To Business B2b Business | 12,995,131,000 | 14,483,935,000 | 14,033,543,000 | 12,247,430,000 |
| Drugs | 12,572,634,000 | 13,883,055,000 | 13,398,162,000 | 11,649,921,000 |
| Nutritional Supplements | 554,789,000 | 631,122,000 | 550,464,000 | 434,685,000 |
| Other Products | 111,097,000 | 170,229,000 | 201,832,000 | 233,690,000 |
| Business To Consumer B2c Business | 408,305,000 | 357,975,000 | 261,197,000 | 223,217,000 |
| Medical Supplies And Devices | 164,916,000 | 157,504,000 | 144,282,000 | 152,351,000 |
| Service | 113,262,000 | 106,219,000 | 106,509,000 | 85,376,000 |
| Mp Service | 68,477,000 | 70,271,000 | 65,536,000 | 56,749,000 |
| Service Other | 44,785,000 | 35,948,000 | 40,973,000 | 28,627,000 |